Intracellular Th Stock Today

ITCI Stock  USD 69.72  2.39  3.55%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 42

 
100  
 
Zero
Below Average
Intracellular is trading at 69.72 as of the 28th of March 2024. This is a 3.55 percent up since the beginning of the trading day. The stock's open price was 67.33. Intracellular has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Intracellular Th are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of September 2023 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of January 2014
Category
Healthcare
Classification
Health Care
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. The company has 96.81 M outstanding shares of which 3.31 M shares are currently shorted by private and institutional investors with about 4.42 trading days to cover. More on Intracellular Th

Moving against Intracellular Stock

  0.62YS YS Biopharma Report 22nd of April 2024 PairCorr
  0.45MDWD Mediwound Financial Report 4th of June 2024 PairCorr

Intracellular Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Intracellular's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Intracellular or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ChairmanSharon Mates
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Intracellular report their recommendations after researching Intracellular's financial statements, talking to executives and customers, or listening in on Intracellular's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Intracellular Th. The Intracellular consensus assessment is calculated by taking the average forecast from all of the analysts covering Intracellular.
Financial Strength
Based on the analysis of Intracellular's profitability, liquidity, and operating efficiency, Intracellular Th is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. Financial strength of Intracellular Th is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.670.6346
Notably Up
Slightly volatile
Total Current Liabilities129.7 M123.5 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total10 M13.3 M
Way Down
Slightly volatile
Total Assets410.9 M728.3 M
Way Down
Slightly volatile
Total Current Assets428.9 M667.8 M
Way Down
Slightly volatile
Intracellular's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Intracellular's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Intracellular's financial leverage. It provides some insight into what part of Intracellular's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Intracellular's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Intracellular deploys its capital and how much of that capital is borrowed.
Liquidity
Intracellular cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 16.94 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Intracellular Th has a current ratio of 9.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Intracellular until it has trouble settling it off, either with new capital or with free cash flow. So, Intracellular's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intracellular Th sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intracellular to invest in growth at high rates of return. When we think about Intracellular's use of debt, we should always consider it together with cash and equity.

End Period Cash Flow

156.99 Million
Intracellular Th (ITCI) is traded on NASDAQ Exchange in USA. It is located in 430 East 29th Street, New York, NY, United States, 10016 and employs 610 people. Intracellular is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.52 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intracellular's market, we take the total number of its shares issued and multiply it by Intracellular's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Intracellular Th conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 96.81 M outstanding shares of which 3.31 M shares are currently shorted by private and institutional investors with about 4.42 trading days to cover. Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64.
Check Intracellular Probability Of Bankruptcy
Ownership Allocation
Intracellular Th has a total of 96.81 Million outstanding shares. The majority of Intracellular Th outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intracellular to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intracellular Th. Please pay attention to any change in the institutional holdings of Intracellular Th as this could imply that something significant has changed or is about to change at the company. Also note that almost nine hundred sixty-eight thousand seventy-two invesors are currently shorting Intracellular expressing very little confidence in its future performance.
Check Intracellular Ownership Details

Intracellular Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of Intracellular jumping above the current price in 90 days from now is about 38.64%. The Intracellular Th probability density function shows the probability of Intracellular stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.532. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Intracellular will likely underperform. Additionally, intracellular Th has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 69.72HorizonTargetOdds Above 69.72
61.08%90 days
 69.72 
38.64%
Based on a normal probability distribution, the odds of Intracellular to move above the current price in 90 days from now is about 38.64 (This Intracellular Th probability density function shows the probability of Intracellular Stock to fall within a particular range of prices over 90 days) .

Intracellular Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Intracellular that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intracellular's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intracellular's value.
InstituionRecorded OnShares
Alliancebernstein L.p.2023-12-31
1.8 M
Franklin Resources Inc2023-12-31
1.8 M
Wellington Management Company Llp2023-12-31
1.8 M
Gw&k Investment Management, Llc2023-12-31
1.6 M
Macquarie Group Ltd2023-12-31
1.6 M
Clearbridge Advisors, Llc2023-12-31
1.6 M
Holocene Advisors, Lp2023-09-30
1.4 M
Pictet Asset Manangement Sa2023-12-31
1.3 M
T. Rowe Price Associates, Inc.2023-12-31
1.3 M
Fmr Inc2023-12-31
11.5 M
Vanguard Group Inc2023-12-31
9.1 M
View Intracellular Diagnostics

Intracellular Historical Income Statement

Intracellular Th Income Statement is one of the three primary financial statements used for reporting Intracellular's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Intracellular Th revenue and expense. Intracellular Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Intracellular's Research Development is increasing as compared to previous years. The Intracellular's current Cost Of Revenue is estimated to increase to about 43.9 M, while Operating Income is projected to decrease to (167.4 M). View More Fundamentals

Intracellular Stock Against Markets

Picking the right benchmark for Intracellular stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Intracellular stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Intracellular is critical whether you are bullish or bearish towards Intracellular Th at a given time. Please also check how Intracellular's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intracellular without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Economic Indicators Now

   

Economic Indicators

Top statistical indicators that provide insights into how an economy is performing
All  Next Launch Module

Intracellular Corporate Directors

Intracellular corporate directors refer to members of an Intracellular board of directors. The board of directors generally takes responsibility for the Intracellular's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Intracellular's board members must vote for the resolution. The Intracellular board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Intracellular Stock?

Before investing in Intracellular, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Intracellular. To buy Intracellular stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Intracellular. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Intracellular stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Intracellular Th stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Intracellular Th stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Intracellular Th, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Intracellular Stock please use our How to Invest in Intracellular guide.

Already Invested in Intracellular Th?

The danger of trading Intracellular Th is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Intracellular is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Intracellular. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Intracellular Th is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Intracellular Stock analysis

When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
CEOs Directory
Screen CEOs from public companies around the world
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.46)
Revenue Per Share
4.843
Quarterly Revenue Growth
0.503
Return On Assets
(0.13)
Return On Equity
(0.22)
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.